Killer Consequence of Liver Disease: Market Demands New Therapies for Hepatocellular Carcinoma

ISSN： 1176-3469

Source： Pharmaceutical & Diagnostic Innovation, Vol.3, Iss.2, 2005-01, pp. : 10-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Liver-Directed Therapies for Hepatocellular Carcinoma

By Arciero Cletus A. Sigurdson Elin R.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 8, 2006-09 ,pp. : 768-774

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Transarterial therapies for hepatocellular carcinoma

By Sangro Bruno D'Avola Delia Iññarrairaegui Mercedes Prieto Jesus

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 7, 2011-05 ,pp. : 1057-1073

Informa Healthcare

Access to resources Recommend Favorite

Systemic therapies for hepatocellular carcinoma

By Palmer Daniel H Hussain Syed A Johnson Philip J

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 12, 2004-12 ,pp. : 1555-1568

Informa Healthcare

Access to resources Recommend Favorite

Targeted Therapies in Hepatocellular Carcinoma

Current Medicinal Chemistry, Vol. 21, Iss. 8, 2014-03 ,pp. : 966-974

Bentham Science Publishers

Access to resources Recommend Favorite

Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy

Current Drug Targets, Vol. 17, Iss. 2, 2016-02 ,pp. : 239-251

Bentham Science Publishers

Access to resources Recommend Favorite